Open Access Article

Cancer Surveillance Behaviors in Women Presenting for Clinical BRCA Genetic Susceptibility Testing

Lois J. Loescher

Kyung Hee Lim

Ofri Leitner

Jessica Ray

Joyce D'Souza

Cary M. Armstrong

health behaviors, genetics
ONF 2009, 36(2), E57-E67. DOI: 10.1188/09.ONF.E57-E67

Purpose/Objectives: To investigate cancer surveillance behaviors of women at risk for hereditary breast and ovarian cancer (HBOC) who presented for clinical BRCA cancer susceptibility testing, specifically to describe cancer surveillance behaviors and reasons for not engaging in behaviors, compare surveillance behaviors with existing surveillance guidelines, and evaluate associations of cancer surveillance behaviors with BRCA results.

Design: Cross-sectional, descriptive.

Setting: Genetic risk-assessment programs in a National Cancer Institute-designated comprehensive cancer center and a community cancer center, both in the southwestern region of the United States.

Sample: Purposive sample of 107 at-risk women.

Methods: Self-report survey.

Main Research Variables: Breast and ovarian cancer surveillance behaviors and BRCA test results.

Findings: Ninety percent of participants had a personal history of breast cancer; 84% had a negative BRCA result. About 60% of participants engaged in at least the minimum recommended breast cancer surveillance behaviors, but 70% had suboptimal ovarian cancer surveillance behaviors. Lack of physician recommendation was the most frequently reported reason for not having surveillance procedures. BRCA results were not associated with the breast cancer surveillance categories and the ovarian cancer surveillance recommendations.

Conclusions: Although most participants were not carriers of a mutation, the presence of other risk factors for breast and ovarian cancer dictates continued cancer surveillance. At-risk women may not be informed adequately about cancer surveillance.

Implications for Nursing: Healthcare providers should be aware of changing breast and ovarian cancer surveillance recommendations and counsel their at-risk patients accordingly.

Jump to a section

    References

    American Cancer Society. (2006a). Can ovarian cancer be found early? Retrieved January 8, 2008, from http://www.cancer.org/docroot/CRI/content/CRI_2_4_3X_Can_ovarian_cancer_be_found_early_33.asp?sitearea=
    American Cancer Society. (2006b). Cancer prevention and early detection facts and figures. Atlanta, GA: Author.
    American College of Preventive Medicine. (2005). Screening asymptomatic women for ovarian cancer: American College of Preventive Medicine practice policy statement. Retrieved November 29, 2007, 2007, from http://www.acpm.org/ovary.htm
    American Society of Clinical Oncology. (1996). Statement of the American Society of Clinical Oncology: Genetic testing for cancer susceptibility, adopted on February 20, 1996. Journal of Clinical Oncology, 14(5), 1730-1740.
    American Society of Clinical Oncology. (2003). American Society of Clinical Oncology policy statement update: Genetic testing for cancer susceptibility. Journal of Clinical Oncology, 21(12), 2397-2406.
    American Society of Human Genetics. (1994). Statement of the American Society of Human Genetics on genetic testing for breast and ovarian cancer predisposition. American Journal of Human Genetics, 55(5), i-iv.
    Andrieu, N., Easton, D. F., Chang-Claude, J., Rookus, M. A., Brohet, R., Cardis, E., et al. (2006). Effect of chest X-rays on the risk of breast cancer among BRCA1/2 mutation carriers in the international BRCA1/2 carrier cohort study: a report from the EMBRACE, GENEPSO, GEO-HEBON, and IBCCS Collaborators' Group. Journal of Clinical Oncology, 24(21), 3361-3366.
    Botkin, J. R., Smith, K. R., Croyle, R. T., Baty, B. J., Wylie, J. E., Dutson, D., et al. (2003). Genetic testing for a BRCA1 mutation: Prophylactic surgery and screening behavior in women 2 years post testing. American Journal of Medical Genetics, 118A(3), 201-209.
    Braithwaite, D., Emery, J., Walter, F., Prevost, A. T., & Sutton, S. (2006). Psychological impact of genetic counseling for familial cancer: A systematic review and meta-analysis. Familial Cancer, 5(1), 61-75.
    Brekelmans, C. T., Seynaeve, C., Bartels, C. C., Tilanus-Linthorst, M. M., Meijers-Heijboer, E. J., Crepin, C. M., et al. (2001). Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk. Journal of Clinical Oncology, 19(4), 924-930.
    Burke, W. (2002). Genetic testing. New England Journal of Medicine, 347(23), 1867-1875.
    Burke, W., Daly, M., Garber, J., Botkin, J., Kahn, M. J., Lynch, P., et al. (1997). Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium. JAMA, 277(12), 997-1003.
    Claes, E., Evers-Kiebooms, G., Decruyenaere, M., Denayer, L., Boogaerts, A., Philippe, K., et al. (2005). Surveillance behavior and prophylactic surgery after predictive testing for hereditary breast/ovarian cancer. Behavioral Medicine, 31(3), 93-105.
    Couch, F. J., DeShano, M. L., Blackwood, M. A., Calzone, K., Stopfer, J., Campeau, L., et al. (1997). BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. New England Journal of Medicine, 336(20), 1409-1415.
    Daly, M. B. (2004). Tailoring breast cancer treatment to genetic status: The challenges ahead. Journal of Clinical Oncology, 22(10), 1776-1777.
    DNAdirect (2009). Who should consider testing for hereditary breast and ovarian cancer? Retrieved February 14, 2009, from http://www.dnadirect.com/web/article/testing-for-genetic-disorders/breast-and-ovarian-cancer-risk/15/who-should-consider-testing
    Donovan, H. S., Hartenbach, E. M., & Method, M. W. (2005). Patient-provider communication and perceived control for women experiencing multiple symptoms associated with ovarian cancer. Gynecologic Oncology, 99(2), 404-411.
    Dorval, M., Gauthier, G., Maunsell, E., Dugas, M. J., Rouleau, I., Chiquette, J., et al. (2005). No evidence of false reassurance among women with an inconclusive BRCA1/2 genetic test result. Cancer Epidemiology, Biomarkers and Prevention, 14(2), 2862-2867.
    Easton, D. F., Hopper, J. L., Thomas, D. C., Antoniou, A., Pharoah, P. D., Whittemore, A. S., et al. (2004). Breast cancer risks for BRCA1/2 carriers. Science, 306(5705), 2187-2191.
    Emmons, K. M., Kalkbrenner, K. J., Klar, N., Light, T., Schneider, K. A., & Garber, J. E. (2000). Behavioral risk factors among women presenting for genetic testing. Cancer Epidemiology, Biomarkers and Prevention, 9(1), 89-94.
    Esserman, L., & Hylton, N. (2005). The Gundry article reviewed. Oncology, 19(2), 170-174.
    Frank, T. S., Deffenbaugh, A. M., Reid, J. E., Hulick, M., Ward, B. E., Lingenfelter, B., et al. (2002). Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: Analysis of 10,000 individuals. Journal of Clinical Oncology, 20(6), 1480-1490.
    Gayther, S. A., Russell, P., Harrington, P., Antoniou, A. C., Easton, D. F., & Ponder, B. A. (1999). The contribution of germline BRCA1 and BRCA2 mutations to familial ovarian cancer: No evidence for other ovarian cancer-susceptibility genes. American Journal of Human Genetics, 65(4), 1021-1029.
    Ghosh, K., Hartmann, L., & Brandt, K. R. (2004). The Wood article reviewed. Oncology, 18(1), 39-42.
    Gundry, K. R. (2005). The application of breast MRI in staging and screening for breast cancer. Oncology, 19(2), 159-169.
    Isaacs, C., Peshkin, B. N., Schwartz, M., Demarco, T. A., Main, D., & Lerman, C. (2002). Breast and ovarian cancer screening practices in healthy women with a strong family history of breast or ovarian cancer. Breast Cancer Research and Treatment, 71(2), 103-112.
    Kash, K. M., Holland, J. C., Halper, M. S., & Miller, D. G. (1992). Psychological distress and surveillance behaviors of women with a family history of breast cancer. Journal of the National Cancer Institute, 84(1), 24-30.
    Kauff, N. D., Mitra, N., Robson, M. E., Hurley, K. E., Chuai, S., Goldfrank, D., et al. (2005). Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer families. Journal of the National Cancer Institute, 97(18), 1382-1384.
    King, M. C., Marks, J. H., & Mandell, J. B. (2003). Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science, 302(5645), 643-646.
    Kinney, A. Y., Hicken, B., Simonsen, S. E., Venne, V., Lowstuter, K., Balzotti, J., et al. (2007). Colorectal cancer surveillance behaviors among members of typical and attenuated FAP families. American Journal of Gastroenterology, 102(1), 153-162.
    Kuschel, B., Lux, M. P., Goecke, T. O., & Beckmann, M. W. (2000). Prevention and therapy for BRCA1/2 mutation carriers and women at high risk for breast and ovarian cancer. European Journal of Cancer Prevention, 9(3), 139-150.
    Lerman, C., Daly, M., Sands, C., Balshem, A., Lustbader, E., Heggan, T., et al. (1993). Mammography adherence and psychological distress among women at risk for breast cancer. Journal of the National Cancer Institute, 85(13), 1074-1080.
    Lerman, C., Hughes, C., Croyle, R. T., Main, D., Durham, C., Snyder, C., et al. (2000). Prophylactic surgery decisions and surveillance practices one year following BRCA1/2 testing. Preventive Medicine, 31, 75-80.
    Lerman, C., Lustbader, E., Rimer, B., Daly, M., Miller, S., Sands, C., et al. (1995). Effects of individualized breast cancer risk counseling: A randomized trial. Journal of the National Cancer Institute, 87(4), 286-292.
    Lynch, H. T., & Lynch, J. F. (1991). Familial factors and genetic predisposition to cancer: Population studies. Cancer Detection and Prevention, 15(1), 49-57.
    MacDonald, D. J. (2002). Women's decisions regarding management of breast cancer risk. MedSurg Nursing, 11(4), 183-186.
    MacDonald, D. J., Sarna, L., Uman, G. C., Grant, M., & Weitzel, J. N. (2006). Cancer screening and risk-reducing behaviors of women seeking genetic cancer risk assessment for breast and ovarian cancers [Online exclusive]. Oncology Nursing Forum, 33(2), E27-E35. Retrieved February 6, 2009, from http://ons.metapress.com/content/h307166720r5525q/?p=0b0715b62e524d36a2… http://ons.metapress.com/content/h307166720r5525q/?p=0b0715b62e524d36a22efb7225bfae3a&pi=0
    Madjar, H., Rickard, M., Jellins, J., & Otto, R. (1999). IBUS guidelines for the ultrasonic examination of the breast. IBUS International Faculty. International Breast Ultrasound School. European Journal of Ultrasound, 9(1), 99-102.
    Madlensky, L., Vierkant, R. A., Vachon, C. M., Pankratz, V. S., Cerhan, J. R., Vadaparampil, S. T., et al. (2005). Preventive health behaviors and familial breast cancer. Cancer Epidemiology, Biomarkers and Prevention, 14(10), 2340-2345.
    McInerney-Leo, A., Hadley, D., Kase, R. G., Giambarresi, T. R., Struewing, J. P., & Biesecker, B. B. (2006). BRCA1/2 testing in hereditary breast and ovarian cancer families III: Risk perception and screening. American Journal of Medical Genetics, 140(20), 2198-2206.
    Myriad Genetics Laboratories, Inc. (2007). Hereditary cancer testing. Retrieved March 23, 2008, from http://www.myriadtests.com/
    National Comprehensive Cancer Network. (2007). NCCN Clinical Practice Guidelines in Oncology™: Breast cancer screening and diagnosis [v.1.2007]. Retrieved February 6, 2009, from http://www.nccn.org/professionals/physician_gls/PDF/breast-screening.pdf
    Oldenburg, R. A., Meijers-Heijboer, H., Cornelisse, C. J., & Devilee, P. (2007). Genetic susceptibility for breast cancer: How many more genes to be found? Critical Reviews in Oncology/Hematology, 63(2), 125-149.
    Petrucelli, N., Daly, M. B., Bars Culver, J. O., Levy-Lahad, E., & Feldman, G. L. (2005). BRCA1 and BRCA2 hereditary breast/ovarian cancer. Retrieved January 8, 2008, from http://www.geneclinics.org/servlet/access?db=geneclinics&site=gt&id=8888891&key=StY9BaIVS9ayW&gry=&fcn=y&fw=ZsLL&filename=/profiles/brca1/index.html
    Pisano, E. D., Gatsonis, C., Hendrick, E., Yaffe, M., Baum, J. K., Acharyya, S., et al. (2005). Diagnostic performance of digital versus film mammography for breast-cancer screening. New England Journal of Medicine, 353(17), 1773-1783.
    Ray, J. A., Loescher, L. J., & Brewer, M. (2005). Risk-reduction surgery decisions in high-risk women seen for genetic counseling. Journal of Genetic Counseling, 14(6), 473-484.
    Rogozinska-Szczepka, J., Utracka-Hutka, B., Grzybowska, E., Maka, B., Nowicka, E., Smok-Ragankiewicz, A., et al. (2004). BRCA1 and BRCA2 mutations as prognostic factors in bilateral breast cancer patients. Annals of Oncology, 15(9), 1373-1376.
    Saslow, D., Boetes, C., Burke, W., Harms, S., Leach, M. O., Lehman, C. D., et al. (2007). American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA: A Cancer Journal for Clinicians, 57(2), 75-89.
    Scheuer, L., Kauff, N., Robson, M., Kelly, B., Barakat, R., Satagopan, J., et al. (2002). Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. Journal of Clinical Oncology, 20(5), 1260-1268.
    Schwartz, M. D., Peshkin, B. N., Hughes, C., Main, D., Isaacs, C., & Lerman, C. (2002). Impact of BRCA1/BRCA2 mutation testing on psychologic distress in a clinic-based sample. Journal of Clinical Oncology, 20(2), 514-520.
    Sifri, R., Gangadharappa, S., & Acheson, L. S. (2004). Identifying and testing for hereditary susceptibility to common cancers. CA: A Cancer Journal for Clinicians, 54(6), 309-326.
    Smith, A., Moran, A., Boyd, M. C., Bulman, M., Shenton, A., Smith, L., et al. (2007). Phenocopies in BRCA1 and BRCA2 families: Evidence for modifier genes and implications for screening. Journal of Medical Genetics, 44(1), 10-15.
    Smith, R. A., Saslow, D., Sawyer, K. A., Burke, W., Costanza, M. E., Evans, W. P., III, et al. (2003). American Cancer Society guidelines for breast cancer screening: Update 2003. CA: A Cancer Journal for Clinicians, 53(3), 141-169.
    Thull, D. L., & Vogel, V. G. (2004). Recognition and management of hereditary breast cancer syndromes. Oncologist, 9(1), 13-24.
    U. S. Preventive Services Task Force. (2004). Screening for ovarian cancer: Recommendation statement. Retrieved January 8, 2008, from http://www.ahrq.gov/clinic/3rduspstf/ovariancan/ovcanrs.htm
    Warner, E., Plewes, D. B., Hill, K. A., Causer, P. A., Zubovits, J. T., Jong, R. A., et al. (2004). Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA, 292(11), 1317-1325.
    Watson, P., Butzow, R., Lynch, H. T., Mecklin, J. P., Jarvinen, H. J., Vasen, H. F., et al. (2001). The clinical features of ovarian cancer in hereditary nonpolyposis colorectal cancer. Gynecologic Oncology, 82(2), 223-228.
    Weitzel, J. N., McCaffrey, S. M., Nedelcu, R., MacDonald, D. J., Blazer, K. R., & Cullinane, C. A. (2003). Effect of genetic cancer risk assessment on surgical decisions at breast cancer diagnosis. Archives of Surgery, 138(12), 1323-1328.
    Wood, W. C. (2004). Advising women at high risk of breast cancer. Oncology, 18(1), 28-32.
    Yusoff, I. F., Hoffman, N. E., & Ee, H. C. (2002). Colonoscopic surveillance for family history of colorectal cancer: Are NHMRC guidelines being followed? Medical Journal of Australia, 176(4), 151-154.